About US
Contact us
-
FDA’s Gottlieb pushes new generics rules to encourage price competitionThe FDA’s role in drug development has always been to green light safe and effective drugs—not to influence how companies price them. But that was before consumers protested price hikes on Mylan’s Epi2017/9/21
-
Asthma’s a real bear in Boehringer Ingelheim’s new TV campaign for Spiriva RespimatWant to know what asthma feels like? Try a crushing bear hug. That’s what patients told Boehringer Ingelheim, informing its latest campaign for Spiriva Respimat as a treatment for asthma. In new TV2017/9/21
-
Judge tosses U.S. lawsuit against GSK from private eyes imprisoned in ChinaGlaxoSmithKline has worked hard to put 2013’s China bribery scandal behind it. And a U.S. judge just gave it an assist in that department. U.S. District Judge Nitza Quiñones Alejandro in Phi2017/9/20
-
Endo, feeling the pricing squeeze, could be the next generics player on the hunt for M&A: analystLate last month, reports said Impax Labs may be looking to bulk up in the face of industry-wide generics pricing pressure with a deal for Amneal. And at least one analyst thinks it may make sense for2017/9/20
-
Sanofi tasks insider Stefan Oelrich with a tough job: Growing diabetes and PraluentSanofi has turned to one of its own to take the reins of its global diabetes and cardiovascular business. Stefan Oelrich, who’s been leading that operation in North America since July, is moving up to2017/9/19
-
Promising Ebola vaccines from Merck, Johnson & Johnson win BARDA fundingEven though the devastating Ebola outbreak in West Africa has ended, U.S. officials and top pharmas aren't letting up on their vaccine development efforts against the virus. Now, the U.S. government2017/9/19
-
Allergan again in eye of the legal storm for foiling competition to RestasisAllergan is again being accused of using unfair tactics to dodge competition for its eye drug Restasis as Shire takes to the courts to try to defeat exclusive contracts it says have kept its competing2017/9/18
-
Does Pfizer really want Bristol-Myers? Likely, says one analyst. What's it waiting for?Investors have had a pointed question for Credit Suisse analysts lately: Is Pfizer buying Bristol-Myers Squibb a question of when, not if? The way analyst Vamil Divan sees it, maybeso. “We remain o2017/9/18
-
AstraZeneca, Tesaro and Clovis need to slash the cost of PARP meds, watchdog saysOvarian cancer patients who respondto chemo have some new treatments designed to keep their disease at bay. But a cost-effectiveness watchdog isn’t convinced those meds are worth their price in that s2017/9/15
-
Cher takes on Patrick Soon-Shiong in shareholder suitFor a second time, billionaire Patrick Soon-Shiong has been sued for allegedly pulling a fast one in his takeover of biotech Altor, but this time it is celebrity singer Cher making the accusations.2017/9/15